Automated Volumetric Software in Dementia: Help or Hindrance to the Neuroradiologist?

References

1. 1.↵
   1. Jack CR Jr.,
   2. Knopman DS,
   3. Jagust WJ, et al

   . Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol 2010;9:119–28 doi:10.1016/S1474-4422(09)70299-6 pmid:20083042

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Chouliaras L,
   2. O’Brien JT

   . The use of neuroimaging techniques in the early and differential diagnosis of dementia. Mol Psychiatry 2023;28:4084–97 doi:10.1038/s41380-023-02215-8 pmid:37608222

   CrossRefPubMed
3. 3.↵
   1. Fujita S,
   2. Mori S,
   3. Onda K, et al

   . Characterization of brain volume changes in aging individuals with normal cognition using serial magnetic resonance imaging. JAMA Netw Open 2023;6:e2318153 doi:10.1001/jamanetworkopen.2023.18153 pmid:37378985

   CrossRefPubMed
4. 4.↵
   1. Fyock CA,
   2. Hampstead BM

   . Comparing the relationship between subjective memory complaints, objective memory performance, and medial temporal lobe volumes in patients with mild cognitive impairment. Alzheimers Dement (Amst) 2015;1:242–48 doi:10.1016/j.dadm.2015.03.002 pmid:26191540

   CrossRefPubMed
5. 5.↵
   1. Kawagoe T,
   2. Onoda K,
   3. Yamaguchi S

   . Subjective memory complaints are associated with altered resting-state functional connectivity but not structural atrophy. Neuroimage Clin 2019;21:101675 doi:10.1016/j.nicl.2019.101675 pmid:30642761

   CrossRefPubMed
6. 6.↵
   1. Passeri E,
   2. Elkhoury K,
   3. Morsink M, et al

   . Alzheimer’s disease: treatment strategies and their limitations. Int J Mol Sci 2022;23:13954 doi:10.3390/ijms232213954 pmid:36430432

   CrossRefPubMed
7. 7.↵
   1. Boeve BF,
   2. Boxer AL,
   3. Kumfor F, et al

   . Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations. Lancet Neurol 2022;21:258–72 doi:10.1016/S1474-4422(21)00341-0 pmid:35182511

   CrossRefPubMed
8. 8.↵
   1. Scheltens P,
   2. Launer LJ,
   3. Barkhof F, et al

   . Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: interobserver reliability. J Neurol 1995;242:557–60 doi:10.1007/BF00868807 pmid:8551316

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Rhodius-Meester HF,
   2. Benedictus MR,
   3. Wattjes MP, et al

   . MRI visual ratings of brain atrophy and white matter hyperintensities across the spectrum of cognitive decline are differently affected by age and diagnosis. Front Aging Neurosci 2017;9:117 doi:10.3389/fnagi.2017.00117 pmid:28536518

   CrossRefPubMed
10. 10.↵
    1. Koedam EL,
    2. Lehmann M,
    3. van der Flier WM, et al

    . Visual assessment of posterior atrophy development of a MRI rating scale. Eur Radiol 2011;21:2618–25 doi:10.1007/s00330-011-2205-4 pmid:21805370

    CrossRefPubMed
11. 11.↵
    1. Pemberton HG,
    2. Zaki LA,
    3. Goodkin O, et al

    . Technical and clinical validation of commercial automated volumetric MRI tools for dementia diagnosis-a systematic review. Neuroradiology 2021;63:1773–89 doi:10.1007/s00234-021-02746-3 pmid:34476511

    CrossRefPubMed
12. 12.↵
    1. Hedderich DM,
    2. Dieckmeyer M,
    3. Andrisan T, et al

    . Normative brain volume reports may improve differential diagnosis of dementing neurodegenerative diseases in clinical practice. Eur Radiology 2020;30:2821–29 doi:10.1007/s00330-019-06602-0 pmid:32002640

    CrossRefPubMed
13. 13.↵
    1. Niemantsverdriet E,
    2. Ribbens A,
    3. Bastin C, et al

    . A retrospective Belgian multi-center MRI biomarker study in Alzheimer’s Disease (REMEMBER). J Alzheimers Dis 2018;63:1509–22 doi:10.3233/JAD-171140 pmid:29782314

    CrossRefPubMed
14. 14.↵
    1. Brewer JB

    . Fully-automated volumetric MRI with normative ranges: translation to clinical practice. Behav Neurol 2009;21:21–28 doi:10.3233/BEN-2009-0226 pmid:19847042

    CrossRefPubMed
15. 15.↵
    1. Pemberton HG,
    2. Goodkin O,
    3. Prados F, et al

    ; Alzheimer’s Disease Neuroimaging Initiative. Automated quantitative MRI volumetry reports support diagnostic interpretation in dementia: a multi-rater, clinical accuracy study. Eur Radiol 2021;31:5312–23 doi:10.1007/s00330-020-07455-8 pmid:33452627

    CrossRefPubMed
16. 16.↵
    1. Dunne RA,
    2. Aarsland D,
    3. O'Brien JT, et al

    . Mild cognitive impairment: the Manchester consensus. Age Ageing 2021;50:72–80 doi:10.1093/ageing/afaa228 pmid:33197937

    CrossRefPubMed
17. 17.↵
    1. Wittens MM,
    2. Sima DM,
    3. Houbrechts R, et al

    . Diagnostic performance of automated MRI volumetry by icobrain dm for Alzheimer’s disease in a clinical setting: a REMEMBER study. J Alzheimers Dis 2021;83:623–39 doi:10.3233/JAD-210450 pmid:34334402

    CrossRefPubMed
18. 18.↵
    1. Ten Kate M,
    2. Barkhof F,
    3. Boccardi M, et al

    ; Geneva Task Force for the Roadmap of Alzheimer’s Biomarkers. Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiol Aging 2017;52:167–82.e1 doi:10.1016/j.neurobiolaging.2016.05.024 pmid:28317647

    CrossRefPubMed
19. 19.↵
    1. Harper L,
    2. Barkhof F,
    3. Fox NC, et al

    . Using visual rating to diagnose dementia: a critical evaluation of MRI atrophy scales. J Neurol Neurosurg Psychiatry 2015;86:1225–33 doi:10.1136/jnnp-2014-310090 pmid:25872513

    Abstract/FREE Full Text
20. 20.↵
    1. Harper L,
    2. Fumagalli GG,
    3. Barkhof F, et al

    . MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases. Brain 2016;139:1211–25 doi:10.1093/brain/aww005 pmid:26936938

    CrossRefPubMed
21. 21.↵
    1. Scheltens P,
    2. Leys D,
    3. Barkhof F, et al

    . Atrophy of medial temporal lobes on MRI in “probable” Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992;55:967–72 doi:10.1136/jnnp.55.10.967 pmid:1431963

    Abstract/FREE Full Text
22. 22.↵
    1. Sarria-Estrada S,
    2. Acevedo C,
    3. Mitjana R, et al

    . Reproducibility of qualitative assessments of temporal lobe atrophy in MRI studies [Aricle in English and Spanish]. Radiologia 2015;57:225–28 doi:10.1016/j.rx.2014.04.002 pmid:24970598

    CrossRefPubMed
23. 23.↵
    1. Min J,
    2. Moon WJ,
    3. Jeon JY, et al

    . Diagnostic efficacy of structural MRI in patients with mild-to-moderate Alzheimer disease: automated volumetric assessment versus visual assessment. AJR Am J Roentgenol 2017;208:617–23 doi:10.2214/AJR.16.16894 pmid:28075620

    CrossRefPubMed
24. 24.↵
    1. Ross DE,
    2. Ochs AL,
    3. DeSmit ME, et al

    ; Alzheimer’s Disease Neuroimaging Initiative. Man versus machine, Part 2: comparison of radiologists' interpretations and Neuroquant measures of brain asymmetry and progressive atrophy in patients with traumatic brain injury. J Neuropsychiatry Clin Neurosci 2015;27:147–52 doi:10.1176/appi.neuropsych.13040088 pmid:25923853

    CrossRefPubMed
25. 25.↵
    1. Bottino CM,
    2. Castro CC,
    3. Gomes RL, et al

    . Volumetric MRI measurements can differentiate Alzheimer’s disease, mild cognitive impairment, and normal aging. Int Psychogeriatr 2002;14:59–72 doi:10.1017/s1041610202008281 pmid:12094908

    CrossRefPubMedWeb of Science
26. 26.↵
    1. Yu Q,
    2. Mai Y,
    3. Ruan Y, et al

    ; Frontotemporal Lobar Degeneration Neuroimaging Initiative. An MRI-based strategy for differentiation of frontotemporal dementia and Alzheimer’s disease. Alzheimers Res Ther 2021;13:23 doi:10.1186/s13195-020-00757-5 pmid:33436059

    CrossRefPubMed
27. 27.↵
    1. Hedderich DM,
    2. Spiro JE,
    3. Goldhardt O, et al

    . Increasing diagnostic accuracy of mild cognitive impairment due to Alzheimer’s disease by user-independent, Web-based whole-brain volumetry. J Alzheimers Dis 2018;65:1459–67 doi:10.3233/JAD-180532 pmid:30175976

    CrossRefPubMed
28. 28.↵
    1. Chagué P,
    2. Marro B,
    3. Fadili S, et al

    . Radiological classification of dementia from anatomical MRI assisted by machine learning-derived maps. J Neuroradiol 2021;48:412–18 doi:10.1016/j.neurad.2020.04.004 pmid:32407907

    CrossRefPubMed
29. 29.↵
    1. Wibawa P,
    2. Matta G,
    3. Das S, et al

    . Bringing psychiatrists into the picture: Automated measurement of regional MRI brain volume in patients with suspected dementia. Aust N Z J Psychiatry 2021;55:799–808 doi:10.1177/0004867421998444 pmid:33726553

    CrossRefPubMed
30. 30.↵
    1. Pressman PS,
    2. Miller BL

    . Diagnosis and management of behavioral variant frontotemporal dementia. Biol Psychiatry 2014;75:574–81 doi:10.1016/j.biopsych.2013.11.006 pmid:24315411

    CrossRefPubMed
31. 31.↵
    1. Bruun M,
    2. Koikkalainen J,
    3. Rhodius-Meester HF, et al

    . Detecting frontotemporal dementia syndromes using MRI biomarkers. Neuroimage Clin 2019;22:101711 doi:10.1016/j.nicl.2019.101711 pmid:30743135

    CrossRefPubMed
32. 32.↵
    1. Perry RJ,
    2. Graham A,
    3. Williams G, et al

    . Patterns of frontal lobe atrophy in frontotemporal dementia: a volumetric MRI study. Dement Geriatr Cogn Disord 2006;22:278–87 doi:10.1159/000095128 pmid:16914925

    CrossRefPubMedWeb of Science
33. 33.↵
    1. Bocchetta M,
    2. Iglesias JE,
    3. Scelsi MA, et al

    . Hippocampal subfield volumetry: differential pattern of atrophy in different forms of genetic frontotemporal dementia. J Alzheimers Dis 2018;64:497–504 doi:10.3233/JAD-180195 pmid:29889066

    CrossRefPubMed
34. 34.↵
    1. Barber R,
    2. Ballard C,
    3. McKeith IG, et al

    . MRI volumetric study of dementia with Lewy bodies: a comparison with AD and vascular dementia. Neurology 2000;54:1304–09 doi:10.1212/wnl.54.6.1304 pmid:10746602

    Abstract/FREE Full Text
35. 35.↵
    1. Roberts RO,
    2. Knopman DS,
    3. Przybelski SA, et al

    . Association of type 2 diabetes with brain atrophy and cognitive impairment. Neurology 2014;82:1132–41 doi:10.1212/WNL.0000000000000269 pmid:24647028

    Abstract/FREE Full Text
36. 36.↵
    1. Jack CR Jr.,
    2. Bennett DA,
    3. Blennow K, et al

    . Contributors. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement 2018;14:535–62 doi:10.1016/j.jalz.2018.02.018 pmid:29653606

    CrossRefPubMed